Richard A Larson

发表

Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Tillmann Krahnke, R. Larson, B. Druker, 2006, Blood.

FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase.

Jie Jin, Chuan He, Zejuan Li, 2017, Cancer cell.

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

Tillmann Krahnke, R. Larson, B. Druker, 2008, Blood.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Francisco Cervantes, Klaus Lechner, Thomas Fischer, 2003, The New England journal of medicine.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Guido Marcucci, Jessica Kohlschmidt, Heiko Becker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lois Shepherd, John D Hines, R. Larson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

Ulrich Mansmann, Guido Marcucci, Manuela Hummel, 2008, Blood.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Suzanne Kamel-Reid, Peter Emanuel, J. Radich, 2012, Blood.

miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia

Zejuan Li, Stephen Arnovitz, Yuanyuan Li, 2012, Proceedings of the National Academy of Sciences.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Christian Langer, Guido Marcucci, M. Caligiuri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Yi Ning, Kellie J Archer, C. Bloomfield, 2006, Blood.

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

John C Reed, Donna S Neuberg, M. Grever, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

J. Holland, R. Larson, C. Decastro, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Bob Löwenberg, Benjamin L Ebert, Pierre Fenaux, 2017, Blood.

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.

Guido Marcucci, Manuela Zucknick, Lianbo Yu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Larson, M. L. Le Beau, Michelle M Le Beau, 2005, Chemico-biological interactions.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Ulrich Mansmann, Xinan Yang, Guido Marcucci, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review Articles (434 articles)

Bob Löwenberg, Pierre Fenaux, Hartmut Döhner, 2008 .

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.

Miao Sun, Eric D Green, Masha Kocherginsky, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Acute lymphoblastic leukaemia: diagnosis and classification.

John Anastasi, R. Larson, J. Anastasi, 2002, Best practice & research. Clinical haematology.

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.

Guido Marcucci, M. Caligiuri, C. Bloomfield, 2006, Blood.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Ricardo Pasquini, Giuseppe Saglio, Andreas Hochhaus, 2010, The New England journal of medicine.

Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Francisco Cervantes, Susan Branford, Andreas Hochhaus, 2017, The New England journal of medicine.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Francisco Cervantes, Thomas Fischer, Alois Gratwohl, 2006, The New England journal of medicine.